Coupling will accelerate the clinical development of A2B antagonists.
Novartis acquired an option to Adenosine Therapeutics’ (ATL) A2B receptor antagonist program. Adenosine Therapeutics will continue to develop the program for the oral treatment of type 2 diabetes, asthma, and other disorders.
“Collaborating with Novartis allows Adenosine Therapeutics to complement its internal research capabilities with those of this well-respected leader in the pharmaceutical industry and provides robust financing to take the program forward into clinical development,” points out Robert S. Capon, CEO and co-founder of Adenosine Therapeutics.
In addition to the drug candidates developed by ATL, Novartis obtained an exclusive option to the U.S. patent that covers the use of A2B receptor antagonists for the treatment of diabetes and related diseases.
